|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 1.66B 1.45B 1.35B 1.24B 2.33B 159B 2.37B 16.06B 6.27B 78.38B 6.21B 6.08B 271B | P/E 2026 * |
4.44x | P/E 2027 * | 22.9x |
|---|---|---|---|---|---|
| Enterprise Value | 1.26B 1.1B 1.03B 941M 1.77B 121B 1.8B 12.18B 4.76B 59.44B 4.71B 4.61B 206B | EV / Sales 2026 * |
0.68x | EV / Sales 2027 * | 0.59x |
| Free-Float |
95.19% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Sarepta Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 63 | 26/06/2017 |
Ryan Wong
DFI | Director of Finance/CFO | 47 | 16/07/2025 |
Ian Estepan
DFI | Director of Finance/CFO | 50 | 14/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Wilsey
CHM | Chairman | 73 | 16/04/2015 |
| Director/Board Member | 87 | 01/06/2010 | |
Richard Barry
BRD | Director/Board Member | 67 | 02/06/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.44% | -8.13% | -1.61% | -35.29% | 2.64B | |
| 0.00% | -2.77% | -13.28% | -19.54% | 317M | |
| 0.00% | +1.05% | -51.12% | - | 52.45M | |
| Average | -0.15% | -1.34% | -22.00% | -27.42% | 1B | |
| Weighted average by Cap. | -0.39% | -7.04% | -3.70% | -33.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.84B 1.62B 1.5B 1.38B 2.59B 177B 2.63B 17.84B 6.97B 87.1B 6.91B 6.76B 301B | 1.41B 1.24B 1.15B 1.06B 1.98B 136B 2.01B 13.66B 5.34B 66.69B 5.29B 5.17B 231B |
| Net income | 419M 368M 342M 314M 590M 40.32B 599M 4.06B 1.59B 19.82B 1.57B 1.54B 68.54B | 67.13M 58.96M 54.83M 50.32M 94.54M 6.46B 96M 651M 254M 3.18B 252M 247M 10.99B |
| Net Debt | -400M -351M -327M -300M -563M -38.52B -572M -3.88B -1.52B -18.94B -1.5B -1.47B -65.47B | -824M -723M -673M -617M -1.16B -79.31B -1.18B -7.99B -3.12B -38.99B -3.09B -3.03B -135B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
